Measure HbF at the single-cell level is no longer optional—it is essential for advancing sickle cell disease care. First, at #ASH2025, Prof. Martin Steinberg, a global authority on HbF, emphasized why this approach is critical for predicting protection against HbS polymerization and optimizing therapeutic strategies.
So, why does it matter? Because of HbF heterocellularity, it’s not the overall HbF percentage or the number of F-cells that determines protection. Instead, what truly matters is the distribution of HbF within each red blood cell. Traditional metrics provide a global view; however, they fail to capture the variability that impacts clinical outcomes.
Consequently, by choosing to measure HbF at the single-cell level, we move from a broad, averaged perspective to a precise, cell-centered approach. This shift is essential for assessing the efficacy of HbF-inducing drugs and gene therapy strategies. Moreover, it allows clinicians and researchers to predict which patients will benefit most from treatments and to tailor interventions accordingly.
At Innovhem, we are pioneering solutions that make single-cell HbF measurement practical and scalable. For example, our technologies integrate advanced analytics and predictive algorithms to transform patient care and accelerate therapeutic development.
Ultimately, this approach doesn’t just improve science—it changes lives. Patients with sickle cell disease deserve therapies that are personalized and effective. Therefore, measuring HbF per cell is the key to unlocking that future.
👉 Learn more about our work on https://innovhem.com/single-cell-hbf
👉 Explore https://innovhem.com/vocpredict, our predictive tool for vaso-occlusive crises
👉 Discover our https://innovhem.com/research
#ASH2025 #SickleCell #HbF #SingleCellAnalytics #Innovhem
